个人简介
Dr. Qiang Xu is a Principal at Decheng Capital and has been with the firm since its inception. He is currently serving on the boards of BCFoods and GYT HealthCare Services.
He has over 14 years of experience from biotechnology start-ups to pharmaceutical companies and also has extensive experience in agricultural biotechnology. He was most recently Vice President of Research at Osel and the principal investigator for multiple grants funded by the NIH and other foundations. Dr. Xu started his biotechnology career at Bayer, worked at Pan Pacific Pharmaceuticals as a director, and Scios as a member of the Alzheimers Disease Discovery Program. He has published over 30 peer reviewed papers, and 50 conference presentations, and is the co-inventor of 10 patents or applications. Dr. Xu received his BS in agronomy and MS in Crop Sciences (with Professor Yu Songlie, an academician of the Chinese Academy of Engineering) and PhD in plant physiology from Kansas State University. He completed his postdoctoral training at the University of California, Berkeley.
He has over 14 years of experience from biotechnology start-ups to pharmaceutical companies and also has extensive experience in agricultural biotechnology. He was most recently Vice President of Research at Osel and the principal investigator for multiple grants funded by the NIH and other foundations. Dr. Xu started his biotechnology career at Bayer, worked at Pan Pacific Pharmaceuticals as a director, and Scios as a member of the Alzheimers Disease Discovery Program. He has published over 30 peer reviewed papers, and 50 conference presentations, and is the co-inventor of 10 patents or applications. Dr. Xu received his BS in agronomy and MS in Crop Sciences (with Professor Yu Songlie, an academician of the Chinese Academy of Engineering) and PhD in plant physiology from Kansas State University. He completed his postdoctoral training at the University of California, Berkeley.
项目需求
投资行业偏好
医疗健康、生物科技
行业细分说明
具有革命性的技术的早期生命科学公司和增长阶段的医疗保健公司
意向运营时间
1年内, 1-3年, 3-5年, 5年以上
意向运营阶段
产品开发, 上线初期, 增长期
偏好投资轮次
天使轮, pre-A轮, A轮, B轮, C轮
偏好投资金额
50-100万, 100-500万, 500-1000万, 1000-5000万, 5000万以上
媒体报道